Evotaz (atazanavir/cobicistat) has been approved for the treatment of HIV-1 infection in adults. It received FDA approval on January 29, 2015.
What is HIV?
HIV (human immunodeficiency virus) is the virus that causes acquired immunodeficiency syndrome (AIDS).
HIV is most commonly transmitted via sexual contact; injected drug use; pregnancy, childbirth, or breast feeding; blood transfusion or organ transplant; and occupational exposure.
The most common signs and symptoms of HIV include flu-like symptoms, fever, swollen glands, sore throat, rash, fatigue, muscle and joint aches and pains, and headache.
Can Evotaz be used as monotherapy (used alone)?
No. Evotaz must be used in combination with other retroviral medications.
In what dosage form and strength will Evotaz be available?
Evotaz will be available to patients as a 300 mg/150 mg tablet, which will contain 300 mg atazanavir (Reyataz) and 150 mg cobicistat (Tybost).
How is Evotaz taken?
The recommended dose of Evotaz is one tablet, taken once daily with food.
What are the side effects of Evotaz?
The most common side effects include nausea, and yellowing of the skin or whites of the eyes.
When will Evotaz be available?
At this time the manufactuer, Bristol-Myers Squibb, has not issued a release date for Evotaz.